Haemonetics Corporation 10-K Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: March 28, 2009
Business Overview: Haemonetics is a global blood management solutions company. It designs, manufactures, and markets automated blood typing and screening systems, blood collection devices, surgical blood salvage systems, and related software and services. The company operates as a single segment, managing three product families: Donor (plasma, blood bank, red cell), Patient (surgical salvage, diagnostics), and Software Solutions and Services.
Key Financial Metrics (Fiscal Year 2009)
| Metric | 2009 (in thousands) | 2008 (in thousands) | % Change |
|---|---|---|---|
| Net Revenues | $597,879 | $516,440 | 15.8% |
| Gross Profit | $308,170 | $257,725 | 19.6% |
| Gross Margin | 51.5% | 49.9% | +160 bps |
| Operating Income | $85,567 | $70,287 | 21.7% |
| Net Income | $59,304 | $51,980 | 14.1% |
| Diluted EPS | $2.27 | $1.94 | 17.0% |
| Cash & Equivalents | $156,721 | $133,553 | N/A |
| Total Debt | $6,038 | $12,363 | (51.2%) |
| Working Capital | $289,530 | $261,757 | 10.6% |
| Current Ratio | 4.1 | 3.7 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 16.7% increase in disposable sales (86.7% of total revenue), primarily due to the TEG diagnostic business acquisition and growth in plasma and surgical/diagnostic lines. Foreign exchange contributed a 2.8% favorable impact.
- Acquisitions: Revenue growth was bolstered by the full-year impact of the Haemoscope (TEG) acquisition and the first-quarter acquisition of Medicell. The company also acquired Altivation Software in March 2009.
- Operating Expenses: Increased 18.8% to $222.6 million. This was largely due to $8.8 million in increased performance-based compensation, $5.5 million in costs related to the Haemoscope acquisition, and $2.0 million in legal costs associated with a patent infringement lawsuit against Fenwal.
- Debt Reduction: Total debt decreased significantly from $12.4 million to $6.0 million, primarily due to the repayment of the Haemonetics Japan Co. Ltd. debt and scheduled mortgage payments.
- Legal Victory: In January 2009, a jury awarded Haemonetics $15.7 million in damages for patent infringement by Fenwal. This amount has not been recorded as a gain pending court rulings on post-trial motions.
Guidance, Outlook, and Risks
- Outlook: Management expects plasma disposable growth rates to moderate to low-to-mid double digits as market growth trends normalize. The company plans to continue investing in R&D for next-generation surgical blood salvage and automated whole blood collection systems.
- Capital Allocation: The Board authorized a new $40.0 million share repurchase program in May 2009. The company completed a $60.0 million repurchase program in fiscal 2009.
- Key Risks:
- Customer Concentration: The Japanese Red Cross Society accounted for 12.2% of net revenues in 2009.
- Foreign Exchange: Approximately 53% of revenues are generated outside the U.S., exposing the company to currency fluctuations (primarily Yen and Euro).
- Regulatory: The company received an FDA Warning Letter in December 2008 regarding cGMP compliance at the Haemoscope facility; management is addressing these concerns.
- Competition: Intense competition in plasma collection (Fenwal, Caridian BCT) and surgical salvage markets.
Investor Verification Checklist
- TEG Integration: Verify the organic growth trajectory of the TEG diagnostic line post-acquisition and the resolution of the FDA Warning Letter regarding the Haemoscope facility.
- Plasma Market Dynamics: Monitor the balance of supply and demand in the plasma market, particularly in the U.S. and Europe, as this drives the high-margin disposable revenue stream.
- Legal Proceeds: Track the status of the Fenwal patent infringement case to determine if the $15.7 million award will be realized and when.
- Customer Concentration: Assess the stability of the relationship with the Japanese Red Cross Society, which represents a significant portion of revenue.
- Share Repurchases: Confirm the execution of the new $40 million share repurchase program authorized in May 2009.